Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock: Insider Ross Moat Sells 27,977 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Ross Moat sold 27,977 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $92.36, for a total transaction of $2,583,955.72. Following the completion of the sale, the chief operating officer owned 10,294 shares in the company, valued at approximately $950,753.84. This represents a 73.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ross Moat also recently made the following trade(s):

• On Friday, October 30th, Ross Moat sold 75,608 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $93.13, for a total transaction of $7,041,373.04.

Kiniksa Pharmaceuticals International Stock Up 2.7%

NASDAQ KNSA traded up $2.49 on Tuesday, hitting $93.29. The stock had a trading volume of 1,021,631 shares, compared to its average volume of 705,858. Kiniksa Pharmaceuticals International, plc has a one year low of $37.02 and a one year high of $98.48. The stock has a market cap of $7.28 billion, a price-to-earnings ratio of 71.76 and a beta of 0.04. The company’s 50-day moving average is $79.39 and its two-hundred day moving average is $60.29.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. The company had revenue of $285.97 million for the quarter, compared to analysts’ expectations of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. On average, sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.26 earnings per share for the current year.

Wall Street Analyst Weigh In

KNSA has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Citigroup boosted their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Canaccord Genuity Group upped their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Wells Fargo & Company increased their price objective on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, October 28th. Finally, The Goldman Sachs Group raised their price objective on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $100.57.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Ethic Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International in the 3rd quarter worth approximately $726,000. Pictet Asset Management Holding SA raised its holdings in shares of Kiniksa Pharmaceuticals International by 41.3% in the 3rd quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock worth $64,182,000 after purchasing an additional 251,578 shares in the last quarter. AlphaCentric Advisors LLC acquired a new stake in Kiniksa Pharmaceuticals International during the third quarter valued at approximately $596,000. Commonwealth Equity Services LLC lifted its stake in Kiniksa Pharmaceuticals International by 2.2% during the third quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock valued at $811,000 after purchasing an additional 237 shares during the last quarter. Finally, Chicago Partners Investment Group LLC acquired a new stake in Kiniksa Pharmaceuticals International during the third quarter valued at approximately $226,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.